In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pandemic Spotlights Tensions Between Profit And Philanthropy

The COVID-19 pandemic has triggered extraordinary levels of collaboration. But competition remains, and many newly created coalitions have yet to be stress tested.

Business Strategies Commercial Companies

Rebuilding Reputations: COVID-19 Presents A Big Responsibility And Opportunity

The global COVID-19 crisis has presented a chance for industry to improve its reputation by highlighting the value of its R&D engines. Pharma executives and observers outline why they are optimistic about a chance to regain public trust.

Coronavirus COVID-19 Commercial Companies

Putting The Patient First: The Challenge And Opportunities To Improve Rare-Disease Therapy Development


Advances in identifying the genetic causes of diseases, and particularly cancers, coupled with regulatory incentives to encourage the development of therapeutic approaches to once poorly managed orphan diseases have fueled a surge in exciting new medicines. To address some of these issues and explore potential solutions, Simbec-Orion in collaboration with Informa Pharma Intelligence convened a round table of experts attending the BIO International Convention

Read More
Data Spotlight

Titans Of Pharma 2020: 15 Leading CEOs Bag $266m In Compensation

See how much the CEOs and R&D heads of the world’s biggest pharma companies get paid, and how those companies are performing.

Making Progress Against Rare Diseases

Biopharmaceutical companies doubled-down on rare disease treatments during the last five years, thanks to a potent combination of scientific discovery and appealing business incentives.

Accessing CAR-T Therapies

Infographic: There are two CAR-T therapies on the market, both of which secured their first approvals in 2017. The pipeline of autologous and allogeneic CAR-T options is busy with several candidates in clinical studies. However, getting approval is only one part of getting these breakthrough therapies to patients.

Growth Explore this Topic

Set Alert for Growth

Latest From Growth

The Golden Winged Warbler And Creating Pharma Supply Chain Immunity

Expert outlines how pharma can create resilient and secure supply chains and some benefits of localization.

Manufacturing India

Pipeline-In-A-Pill: Still A Winning Strategy?

Pipeline-in-a-pill has increasingly entered the biopharma executive’s vernacular, denoting an attractive asset that has considerable sales potential owing to the number of discrete patient populations it can target. While the phrase or concept may be in vogue, in reality it is one of the many guises or iterations of lifecycle management.

Business Strategies Commercial

Pulling Back The Curtain On Biopharma Partnering In Cell And Gene Therapies

Therapeutic areas and unmet needs drive big company decision-making about when and what technologies to bring in from external sources, executives explained during a panel at the 2020 Cell and Gene Therapy Meeting on the Mesa.

Commercial Deals

Innovation Explore this Topic

Set Alert for Innovation

Latest From Innovation

Advancing The Precision Mission At RSNA 2020

RSNA is the next major global medtech event to be run under a virtual format this fall. Under COVID-19, the major medtechs are finding different ways to demonstrate value, as Royal Philips explains.

Innovation Medical Device

New Study Quantifies Value Of AI In European Health Care

Personal data security and the right to health must be balanced as artificial intelligence adoption increases incrementally – but winning “trust” is the key to ongoing success.

Innovation Medical Device

Peptomyc Tackling ‘Undruggable’ Myc For Anticancers

Laura Soucek, one of In Vivo’s 2020 Rising Leaders, is hoping to take Barcelona-based start-up Peptomyc to the next level. The company is nearing the clinic with an inhibitor of the transcription factor Myc, which is involved in the regulation of cellular proliferation, but can also be a driver of cancer.

Clinical Trials Innovation

Leadership Explore this Topic

Set Alert for Leadership

Latest From Leadership

Pharma CEO Pay Trends In India: What Lies Ahead?

In Vivo discusses dimensions around pharma CEO pay in India and whether it should be part of cost management efforts amid the pandemic.

Leadership India

Sandoz Sees Revolution In US Biosimilars Market

Five years on from the first US biosimilar approval, the country’s biosimilars market is starting to fulfil its potential, in part driven by a recent oncology “revolution” according to Sandoz’ Sheila Frame.

Biosimilars Business Strategies

Building The Talent Pipeline Starts With Access For All

Diversity in all forms is critical to innovation in health care, says AstraZeneca’s chief medical officer, Ann Taylor. In an exclusive interview, she talks about the company’s work in mentoring and education, and why tackling issues around diversity and inclusion must be driven by the C-suite alongside community initiatives. 

C-Suite Speaks Business Strategies

Market Access Explore this Topic

Set Alert for Market Access

Latest From Market Access

The Rise And Fall And Long-Term Rise Of Digitally Enabled Health Care

COVID-19 has accelerated the adoption of telehealth, but lasting change will only happen once digital health is institutionalized in health system work flows, says Teladoc Health’s Joe DeVivo.

Business Strategies Coronavirus COVID-19

Snapshot: October Highlights

A selection of articles you might have missed from October 2020, including exclusive interviews with industry leaders and a deeper dive into the Femtech market.

Business Strategies Commercial

Exclusive Interview: Biopharma And A Biden Administration

A Biden administration, if elected, would protect biopharmaceutical innovation, tackle the rising costs of cancer drugs and “promote science, without politics.”

US States North America

Market Intelligence Explore this Topic

Set Alert for Market Intelligence

Latest From Market Intelligence

Pharma R&D’s COVID-19 Scar

Months of pandemic-induced disruption to health care systems and freedom of movement undoubtedly carries a cost. For the biopharmaceutical industry, this can be mitigated by its essential role in providing therapeutic interventions and leading the fightback via prophylactic vaccines. This softens the blow somewhat, certainly compared to other industries that are fully exposed to COVID-19 headwinds.

Research & Development Research and Development Strategies

A Year Of Surprises Shakes Up Off-Patent Industry

After an eventful year for the off-patent industry, the world’s leading generics and biosimilars players have switched places in Generics Bulletin’s newly compiled global sales ranking.

Biosimilars Generic Drugs

Locked And Bolted: How To Create A Data Fortress

Considering the increasing number of biopharmaceutical companies pursuing more virtual and digital tools, the need for world class digital protection is a pressing challenge. In Vivo talks to two cyber security experts about best practice when securing data assets.

Artificial Intelligence Business Strategies
UsernamePublicRestriction

Register